Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China

Rhea-AI Summary

Thermo Fisher Scientific (NYSE:TMO) has partnered with Innoforce to establish a new pharma services facility in Hangzhou, China, aimed at integrated biologics and sterile drug development. Expected to be operational by 2022, this state-of-the-art facility will enhance Thermo Fisher's global pharma network, offering services that align with stringent regulatory guidelines. The collaboration is poised to meet rising demand for biologics in China and facilitate drug development for both regional and global clients.

Positive

• Joint venture with Innoforce expands Thermo Fisher's capabilities in China.
• New facility set to enhance global pharma services network, boosting operational capacity.
• Expected operational date in 2022 aligns with increasing demand for biologics.

Negative

• None.

WALTHAM, Mass. and SHANGHAI, Nov. 6, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Innoforce, a bioinnovation-enabling company, today announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022.

The new state-of-the-art Good Manufacturing Practices (GMP) facility will become part of Thermo Fisher's extensive global pharma services network, which includes leading capabilities for drug product development, biologics manufacturing, sterile fill-finish, clinical trials packaging and logistics. The Hangzhou site will also incorporate stringent quality control processes that meet or exceed regulatory guidelines established by the China National Medical Products Administration (NMPA), the U.S. FDA and appropriate EMEA authorities.

"Our agreement with Innoforce will provide critical support in helping to meet the high demand for biologics in China," said Michel Lagarde, executive vice president, Thermo Fisher Scientific. "The addition of the Hangzhou site will expand our existing global network and provide drug development and manufacturing services for customers in China, as well as for global customers seeking capabilities in the region."

Innoforce CEO Yuling Li said, "To successfully bring novel therapies to market domestically and internationally, emerging biotech companies increasingly need partners with expertise in development and manufacturing and deep global regulatory knowledge. Through our partnership with Thermo Fisher, we can offer an accelerated pathway for biopharmaceutical manufacturers in China – and outside as well – to bring innovative therapies to the world."

Until the site is operational, new and existing customers can access Thermo Fisher's global biologics and steriles network, which includes sites across the U.S., Europe and Asia-Pacific, and then seamlessly transition to the new Hangzhou site after completion.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

About Innoforce Pharmaceuticals

Innoforce is a bioinnovation-enabling corporation located in the heart of Hangzhou Bay Biotech Valley within the Hangzhou Airport Economic Demonstration Area. The founders are global biopharmaceutical industry executives including Innoforce Chairman Dr. Guo-Liang Yu and CEO Dr. Yuling Li and the core management team has extensive international experience and expertise in technology innovation, product development and business operations. The first phase of the Innoforce campus covers 21 acres including biologic process development laboratories, scale-up and R&D labs, and manufacturing facilities for protein, cell and gene therapies. For more information, please visit www.innoforcepharma.com.

Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com

Ken Carter
Phone: 240-421-3838
E-mail: ken.carter@innoforcepharma.com 
Website: www.innoforcepharma.com

Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com

Bing Zhu
Phone: +86 186 2136 8339
E-mail: bing.zhu@innoforcepharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-innoforce-partner-to-establish-biologics-and-steriles-drug-manufacturing-facility-in-china-301167262.html

SOURCE Thermo Fisher Scientific

FAQ

What is the purpose of the new facility established by Thermo Fisher and Innoforce in China?

The new facility will focus on integrated biologics and sterile drug development and manufacturing.

When is the Thermo Fisher facility in Hangzhou expected to be operational?

The facility is expected to be completed in 2022.

How does the new facility impact Thermo Fisher's operations in China?

It expands Thermo Fisher's global pharma services network and enables better service to meet the high demand for biologics in China.

What regulations will the Hangzhou facility comply with?

It will adhere to quality control processes that meet or exceed guidelines from the NMPA, U.S. FDA, and EMEA authorities.